5-Amino-1MQ

NNMT inhibitor that reprograms fat cell metabolism

beginnerMid-range

What is 5-Amino-1MQ?

5-Amino-1MQ is a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that has emerged as a key regulator of fat cell metabolism. NNMT is overexpressed in the white adipose tissue of obese individuals, where it acts as a metabolic brake: it depletes the methyl donor SAM (S-adenosylmethionine) and reduces NAD+ availability, both of which are needed for healthy cellular energy metabolism. By inhibiting NNMT, 5-Amino-1MQ releases this brake and restores metabolic activity in fat cells.

What makes 5-Amino-1MQ unusual in the peptide and fat-loss space is that it targets the fat cell itself rather than appetite, GLP-1 signaling, or thyroid function. Compounds like Semaglutide reduce food intake through appetite suppression. AOD-9604 and HGH Fragment 176-191 mimic growth hormone's lipolytic effects. 5-Amino-1MQ does something different: it reprograms fat cells to be more metabolically active, reversing the dysfunction that makes adipose tissue in obese individuals resistant to fat loss.

The compound is taken orally, which is a significant practical advantage. No reconstitution, no syringes, no injection site management. You take a capsule once or twice daily. This makes it one of the most accessible fat-loss compounds available, and it is often the entry point for people who want metabolic support but are not ready to commit to injectable peptides.

5-Amino-1MQ pairs naturally with MOTS-c for a dual metabolic stack: MOTS-c activates AMPK and improves mitochondrial function, while 5-Amino-1MQ tackles the NNMT bottleneck in fat tissue. For those already on a GLP-1 agonist like Semaglutide, adding 5-Amino-1MQ can address the adipocyte-level metabolic dysfunction that appetite suppression alone does not fix. Explore stacking options with the Peptide Stack Calculator.

How 5-Amino-1MQ Works

5-Amino-1MQ targets a single enzyme, NNMT, but the downstream effects ripple through multiple metabolic pathways:

NNMT Inhibition: NNMT catalyzes the methylation of nicotinamide (a form of vitamin B3) using SAM as the methyl donor. In obese adipose tissue, NNMT is overexpressed, which creates two problems: it depletes SAM (needed for hundreds of methylation reactions in the cell) and generates 1-methylnicotinamide (1-MNA), which has been linked to inflammatory signaling. 5-Amino-1MQ binds to NNMT's active site and blocks this reaction.

NAD+ Restoration: When NNMT is overactive, it diverts nicotinamide away from the NAD+ salvage pathway. NAD+ is essential for mitochondrial energy production, sirtuins (longevity-related enzymes), and fat oxidation. By blocking NNMT, 5-Amino-1MQ allows more nicotinamide to flow into NAD+ synthesis, increasing NAD+ levels in fat tissue. Higher NAD+ means fat cells can actually burn their stored energy.

SAM-Dependent Pathway Activation: With NNMT consuming less SAM, the cellular SAM pool recovers. SAM is the universal methyl donor in human biochemistry, involved in DNA methylation, polyamine synthesis, and the production of creatine, carnitine, and other metabolically active compounds. Restoring SAM availability reactivates these pathways in fat cells.

Adipocyte Shrinkage: In cell culture and animal studies, NNMT inhibition reduces lipid content in fat cells without killing them. The cells become smaller and more metabolically active. This contrasts with approaches that destroy fat cells (like cold-induced lipolysis), which can lead to uneven results.

No CNS Stimulation: 5-Amino-1MQ works entirely at the adipocyte level. It does not cross the blood-brain barrier significantly, does not affect appetite hormones, and does not increase heart rate or blood pressure. The fat loss it produces is metabolic, not stimulant-driven.

Benefits of 5-Amino-1MQ

Fat Loss Without Stimulant Side Effects The primary benefit. By inhibiting NNMT in fat tissue, 5-Amino-1MQ promotes fat loss through improved adipocyte metabolism rather than appetite suppression or thermogenic stimulation. Mouse studies on high-fat diets showed that NNMT inhibition reduced body weight and fat mass significantly compared to controls, without changes in food intake. Users report gradual, steady fat loss over 8-12 weeks, particularly from stubborn areas that have not responded to diet and exercise alone.

Improved Metabolic Health Markers NNMT overexpression correlates with insulin resistance, dyslipidemia, and metabolic syndrome. Inhibiting NNMT improves insulin sensitivity and lipid profiles in animal models. For people with metabolic dysfunction contributing to their fat retention, 5-Amino-1MQ addresses a root cause rather than a downstream symptom.

NAD+ Boosting in Fat Tissue NAD+ decline is a hallmark of aging and metabolic dysfunction. While systemic NAD+ precursors (NMN, NR) aim to raise NAD+ levels body-wide, 5-Amino-1MQ specifically restores NAD+ in adipose tissue by unblocking the nicotinamide salvage pathway. This targeted NAD+ boost reactivates fat cell mitochondria and sirtuin activity. It complements systemic NAD+ strategies like NAD+ supplementation.

Oral Convenience 5-Amino-1MQ is taken as a capsule. No reconstitution, no bacteriostatic water, no syringes. For people who want metabolic support but are not comfortable with injections, this is a major practical advantage. It can serve as a gateway compound before moving to injectable peptides.

Stackability 5-Amino-1MQ targets a unique pathway (NNMT) that does not overlap with GLP-1 agonists, growth hormone peptides, or AMPK activators. This means it stacks cleanly with almost any other fat-loss or metabolic protocol. It adds a dimension of fat-cell-level metabolic activation that other compounds miss.

Side Effects & Safety

Common Side Effects - Mild GI discomfort (nausea, slight stomach upset) when first starting, especially on an empty stomach - Occasional loose stools during the first week - Slight headache in the initial days of use

Less Common Side Effects - Mild dizziness - Temporary changes in appetite - Allergic sensitivity (rare)

Contraindications and Cautions - 5-Amino-1MQ is a research compound. Human clinical trial data is limited, and long-term safety has not been formally established. - The compound is generally well tolerated in available reports, but as with any metabolic modulator, start at the lower dose to assess your individual response. - People taking nicotinamide or NAD+ precursor supplements (NMN, NR) alongside 5-Amino-1MQ may experience amplified effects on NAD+ metabolism. This is not necessarily dangerous, but it is worth monitoring. - Pregnant or breastfeeding women should not use this compound. - People with liver or kidney disease should consult a physician before use, as metabolic byproducts are processed through these organs. - If you are on diabetes medication, monitor blood sugar carefully, as improved insulin sensitivity from NNMT inhibition could affect your dosing needs.

5-Amino-1MQ Dosage Protocols

Protocol	Dose	Frequency	Duration
Standard Fat Loss Protocol	50 mg	Once daily with food	8-12 weeks
Accelerated Protocol	100 mg/day (50 mg twice daily)	Twice daily with meals	8-12 weeks
Metabolic Stack Protocol	50-100 mg/day oral	Once or twice daily	8-12 weeks

Standard Fat Loss Protocol: Start here to assess tolerance. Take with breakfast or lunch. Avoid taking late in the day on the off chance it affects sleep (rare but reported). Most users see gradual results starting around week 4.

Accelerated Protocol: Split the dose between breakfast and lunch. This is the upper range commonly used. Do not exceed 100 mg/day without medical guidance. Better results when combined with regular exercise and a moderate caloric deficit.

Metabolic Stack Protocol: When stacking with MOTS-c or a GLP-1 agonist, start at 50 mg/day and increase only if well tolerated. The combination targets multiple metabolic pathways simultaneously, so starting conservatively is wise.

These are general guidelines for research purposes. Always consult a healthcare professional before use.

Is 5-Amino-1MQ Right for You?

Take our quiz to get a personalized recommendation based on your goals and profile.

Start the Quiz

Stacking 5-Amino-1MQ

Semaglutide

Multi-pathway fat loss: appetite suppression plus adipocyte metabolic activation

Semaglutide at prescribed dose (0.25-2.4 mg/week titrated) + 5-Amino-1MQ at 50-100 mg/day orally. Semaglutide reduces food intake through GLP-1 receptor activation, while 5-Amino-1MQ reprograms fat cells to burn stored energy more efficiently. They target completely different pathways, so the combination can produce better results than either alone.

MOTS-c

Dual metabolic activation: AMPK pathway plus NNMT inhibition

MOTS-c at 5 mg twice weekly (injection) + 5-Amino-1MQ at 50-100 mg/day (oral). Run for 8-12 weeks. MOTS-c activates AMPK for mitochondrial biogenesis and insulin sensitivity, while 5-Amino-1MQ unblocks the NNMT bottleneck in fat tissue. Together they address metabolic dysfunction from two angles.

AOD-9604

Direct lipolysis combined with metabolic reprogramming of fat cells

AOD-9604 at 300 mcg/day (injection) + 5-Amino-1MQ at 50-100 mg/day (oral). Run for 8-12 weeks. AOD-9604 directly stimulates lipolysis (fat breakdown) through HGH fragment mechanisms, while 5-Amino-1MQ ensures the fat cells are metabolically responsive enough to actually release and burn their stored lipids.

Frequently Asked Questions

Is 5-Amino-1MQ actually a peptide?

Technically, no. 5-Amino-1MQ is a small molecule, not a peptide. It is an aminoquinoline compound. However, it is commonly categorized alongside peptides in the metabolic optimization space because it is sold through similar channels and used in similar protocols. Its mechanism of action (NNMT inhibition) is distinct from peptide receptor signaling.

How does 5-Amino-1MQ compare to Semaglutide for fat loss?

They work through completely different mechanisms. Semaglutide suppresses appetite via GLP-1 receptors in the brain. 5-Amino-1MQ reprograms fat cell metabolism by inhibiting NNMT. Semaglutide has much stronger clinical evidence (large Phase 3 trials, FDA approval) and produces more dramatic weight loss (15-20% of body weight). 5-Amino-1MQ produces more modest results but targets a metabolic bottleneck that appetite suppression alone does not address. Many people use both. See the Semaglutide page for a full comparison.

Do I need to diet and exercise while taking 5-Amino-1MQ?

You will get better results if you do. 5-Amino-1MQ improves fat cell metabolism, but it does not override a large caloric surplus. Think of it as removing a metabolic roadblock: once the roadblock is cleared, your diet and exercise efforts become more effective. In mouse studies, fat loss occurred without dietary changes, but human results are likely to vary. A moderate caloric deficit and regular exercise will amplify the compound's effects.

Can 5-Amino-1MQ be combined with NAD+ supplements like NMN?

Yes, and the combination may be synergistic. 5-Amino-1MQ blocks NNMT from diverting nicotinamide away from NAD+ synthesis, while NMN or NR directly provides NAD+ precursors. Together, they boost NAD+ from both sides: increasing supply (NMN) and reducing waste (NNMT inhibition). This has not been formally studied in combination, so start conservatively and monitor how you feel.

How long does it take to see results from 5-Amino-1MQ?

Most users report noticing effects around week 3-4, with more significant body composition changes by week 8-12. The timeline depends on your starting metabolic state, diet, exercise level, and whether you are stacking with other compounds. Do not expect rapid dramatic weight loss like GLP-1 agonists produce. 5-Amino-1MQ works more gradually by shifting fat cell metabolism over time.

Are there any long-term risks from inhibiting NNMT?

This is an open question. NNMT is involved in multiple metabolic processes, and long-term inhibition has not been studied in humans. In animal studies, NNMT inhibition produced no obvious adverse effects over the study periods (typically weeks to months). However, NNMT does play roles in nicotinamide metabolism and potentially in cancer biology, so cycling the compound (8-12 weeks on, 4 weeks off) is a prudent approach until more data is available.

Why is 5-Amino-1MQ oral when most fat-loss peptides are injectable?

5-Amino-1MQ is not a peptide; it is a small molecule aminoquinoline. Small molecules survive stomach acid and digestive enzymes, pass through the intestinal lining, and reach the bloodstream intact. Peptides (chains of amino acids) get broken down by digestive enzymes, which is why most need to be injected. The oral bioavailability of 5-Amino-1MQ is a major practical advantage over injectable alternatives.

Not Sure Which Peptide Protocol Is Right for You?

Take our 2-minute quiz for a personalized recommendation based on your goals and health profile.

Start the Quiz →

Best Peptides for Weight Loss (2026)Read article →

References & Clinical Studies

Medical Disclaimer

This content is for informational and educational purposes only. It is not intended as medical advice and should not replace consultation with a qualified healthcare professional. Peptides discussed here may be unapproved for human use in your jurisdiction. Always consult your doctor before starting any new supplement or peptide protocol.